Skip to main content
. 2016 Aug 4;21(31):30309. doi: 10.2807/1560-7917.ES.2016.21.31.30309

Table 5. Economic costs and productivity losses of West Nile neuroinvasive disease in humans following an epidemic of West Nile virus infection in Belgium, by infection rate scenario among people at risk, estimated at national level, 2012 values.

Economic impact 2%
infection rate scenario
15%
infection rate scenario
Cost in euros Number of patients Cost in euros Number of patients
Visits to a general practitioner 19,987 869a 150,006 6,522a
Hospital charges
Total 3,110,645 869a 23,346,714.00 6,522a
WNND 2,995,179 843b 22,476,278 6,326b
AFP 115,466 26c 870,436 196c
Other
Diagnosis (serology) 18,249 869a 136,962 6,522a
Home care (30-day recovery period after hospital discharge) 1,808,820 773d 13,583,700 5,805d
Work absenteeism (productivity losses) 495,924 120e 2,857,613 587e
Compensation paid to beneficiaries
(after the death of a patient)
940,800 96f 7,026,600 717f
Total 6,394,425 869a 47,101,595 6,522a

AFP; acute flaccid paralysis; NA: not applicable; WNND; West Nile neuroinvasive disease.

AFP occurs in 3% of all WNND cases [39]. Hospitalisation costs are 1.25 higher for AFP cases compared with those for WNND cases [35].

a Number of patients consulting a general practitioner (WNND and AFP cases).

b Number of patients hospitalised for WNND.

c Number of patients hospitalised for AFP.

d Number of hospitalised patients who survived and needed homecare after discharge from hospital.

e Number of hospitalised patients, who are active on the labour market (and have a job) and for whom losses due to work absenteeism were estimated.

f Number of deceased patients.